NCT03283137 2025-02-07Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHLUniversity of ChicagoPhase 1 Active not recruiting20 enrolled
NCT04635683 2022-09-30Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaOhio State University Comprehensive Cancer CenterPhase 1 Withdrawn